International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Enhancing Clinical Decision Support System: Risk Stratification of Hepatological Disorders by Advanced Machine Learning Models

Chandan Pan

Vinod Gupta School of Management, Indian Institute of Technology, Kharagpur, India
chandanpan@kgpian.iitkgp.ac.in

Abstract

Artificial Intelligence (AI) is reshaping healthcare services reflecting the increasing significance of data science for disease prediction. The integration of AI into diagnostic processes helps to optimize many processes in healthcare management. This research emphasis to enhance physician productivity in disease prediction, particularly concerning chronic hepatological disorders, to increase care management. It proposes a comprehensive framework for the incorporation of ensemble machine learning models into clinical practice. Furthermore, healthcare operations and strategic management data, informed by statistical analysis and AI can facilitate the identification of critical success factors for the healthcare management system through the proposed digital Healthcare Transformation.

The methodology is driven by patient data derived taken from health systems at the University of California, Irvine (UCI), and encompasses the mapping of management diagnostics workflows. To refine the process of illness diagnosis, the proposed approach formulates a clinical decision-making algorithm leveraging contemporary AI technologies. The objectives of this study encompass mitigating physician burnout with streamlining care administration and augmenting diagnostic accuracy. This research highlights the importance of enhancing diagnostic accuracy and maximizing physician effectiveness for the treatment of liver diseases.

Enhanced model performance efficiency, as indicated by KPIs is achieved through the implementation of a state-of-the-art ensemble machine learning methodology. Our approach also emphasis on the comparative predictive strengths of individual Artificial Intelligence algorithms including Gradient Boosting (GB), Random Forest Classifier (RF) and Artificial Neural Network (ANN). To improve the accuracy and reliability of Hepatological Disorder predictions, the proposed Voting Ensemble Classifier integrates the outputs of these algorithms, thus addressing the limitations of using in a single model which may be vulnerable to data noise or overfitting.

Keywords: Advanced Machine Learning, Health Analytics, Clinical Decision Support, Ensemble Classifier

1. Introduction:

Early diagnosis and appropriate treatment in Liver diseases significantly improve the chances of survival. Healthcare providers can leverage machine learning (ML), a data-centric approach, to aid in the diagnosis of liver-related ailments.

Recent progress in medical detection technologies has led to the accumulation of considerable health data. Consequently, the application of big data analysis tools is essential for processing this data, thereby yielding insights that facilitate disease diagnosis, personalized treatment strategies, and other medical applications.

The growing number of people with liver disease is a result of several factors, including excessive alcohol use, exposure to harmful substances, and the consumption of contaminated food, drinks, and medicines. Using this dataset, we can evaluate AI-based prediction algorithms. This could help doctors and improve the overall efficiency of hospital operations.

The global burden of liver diseases, including conditions like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hepatitis, is substantial and growing[1]. Early and accurate detection is paramount for effective treatment and improved patient outcomes. Traditional diagnostic methods often rely on a combination of subjective assessments and limited data analysis[2]. However, recent advancements in AI are driving a paradigm shift in gastroenterology and hepatology by delivering cutting-edge tools for disease screening, diagnosis, and treatment[3].

Recent studies demonstrate that ML models are achieving diagnostic performance that is comparable to expert clinicians and, in some cases surpassing the performance of human experts in specific areas like medical image analysis and pathology[3]. The ability of these models to process large amounts of data to make predictions about future risk A number of supervised learning techniques have been successfully applied to this problem. The success of these models, particularly ensemble methods that combine multiple classifiers, indicates that the first stage of the proposed system is grounded in a well-established and validated field of inquiry[4]

2. Literature Review And Motivations

The choice of liver disease as the focal point of this investigation stems from a confluence of epidemiological, clinical, and analytical considerations. Hence rendering it as a significant and impactful area for the deployment of AI-driven predictive analytics within healthcare management.

Liver disease has a critical and increasing role in the worldwide disease burden, which is markedly disproportionate to the focus it gets in public health discussions. The liver helps in regulating metabolism, detoxifying, making proteins, bile, modulating the immune system and making coagulation factors. This makes it one of the most functionally complex organs in the body [5].

These are all diseases that often show up late and are not caught early. According to the Global Burden of Disease Study (GBD, 2019), liver cirrhosis and other chronic liver diseases killed more than a million people each year. In US, the annual economic burden of chronic liver disease and cirrhosis is estimated few billion in direct medical costs with liver transplantation adding a further USD annually [6].

Himmelstein et al. [7] conducted a significant cross-national comparative investigation in the field of healthcare administrative costs and revenue cycle management, revealing that administrative complexity across eight nations: Canada, England, Scotland, Wales, France, Germany, the Netherlands, and the United States is a primary factor contributing to increased healthcare costs.

The liver is one of the most critical internal organs for the maintenance of life and is the largest. It is located in the upper right quadrant of the abdomen. The liver performs over 500 critical biochemical functions. This is essential for the body's metabolism, immunity, detoxification and overall balance. The liver plays a critical function in human health and can have life-threatening consequences if it fails.

Metabolism is one of the liver's most critical functions. The body regulates carbohydrate metabolism by storing excess glucose as glycogen and discharging it back into the circulation when energy is required. It also regulates lipid metabolism by synthesizing cholesterol, triglycerides, lipoproteins and degrading fatty acids to generate energy. The liver is responsible for the production of essential plasma proteins such as albumin and coagulation factors, which are essential for the maintenance of fluid balance and the prevention of haemorrhage and processing of amino acids for protein metabolism.

Detoxification and refuse management are additional critical functions. Toxins, narcotics, and alcohol are removed from the bloodstream by the liver, which then converts them into less toxic substances. It converts ammonia, a toxic byproduct of protein metabolism, into urea, which is eliminated by the kidneys. Furthermore, it produces the proteins necessary for clotting which helps stop bleeding when a person is hurt.

Unlike the kidneys, which can temporarily replace some of their functions through dialysis, the liver's complex functions cannot be replicated by any external device. Liver damage often goes unnoticed until it has advanced, given its silent role in numerous vital processes. Consequently, early identification and treatment of liver diseases are crucial.

Nahar [8] investigated several ensemble approaches (AdaBoost, LogitBoost, RF etc Models) to predict liver illness where the authors analyzed the performance of several machine learning approaches throughout many iterations. The performance of the Model were assessed by Accuracy, RMSE (Root Mean Square Error), TPR (True Positive Rate), FPR (False Positive Rate), and ROC (Receiver Operating Characteristic Curve) methodologies. It was demonstrated that LogitBoost achieved a benchmark performance of 71.53%.

Babu et al. [11] used the K-Means Clustering approach for identifying liver patients in their research by implementating many classification models. After constructing the classification model, NBC attained an accuracy of 56%, KNN obtained 64%, and C4.5 reached 69%.
Gupta et al. [10] conducted a comparison of several machine learning algorithms, including GB, XGB, and LGB for predicting liver diseases using ILPD dataset. Omar S. Soliman et al. [10] suggested a hybrid classification method using the Particle Swarm Optimization (PSO) algorithm and Least Squares Support Vector Machine Technique [2].

The project's main goal is to develop and validate this AI ensemble Pipeline Model. It aims to show its ability to combine different AI algorithms and address complex disease detection problem. The expected impact is to improve early detection rates for liver disease by using ensemble ML methods with a higher accuracy, AUC and Precision Rate.

3. Datasets Description

A comprehensive dataset[9] of liver patients, including 583 instances with 11 explanatory variables, is used from the University of California, Irvine (UCI) sites. The data was acquired in recent years from a broad cohort of patients, ranging from infants (under 4 years) to the elderly (80+ years). The dataset comprises of both Qualitative and Quantitative attributes in conjunction with appropriate hyperparameter tuning and feature selection, several preprocessing approaches must be used to prepare the proposed model.

Explanatory Variable Analysis: Blood Protein and Engines Levels in Patients

Blood biochemical parameters play a critical role in assessing liver function, nutritional status, and overall physiological health. The analysis of bilirubin, protein levels, and their associated ratios provides valuable insights into hepatic performance and disease progression.

Total Bilirubin (TB) represents the overall concentration of bilirubin present in the bloodstream . In the observed patient dataset, total bilirubin levels ranged from 0.4 to 75 mg/dL, which significantly exceeds the normal reference values of 0.1–1.2 mg/dL in adults.

Direct Bilirubin (DB) measures the water-soluble, conjugated form of bilirubin, reflecting the liver's efficiency in processing and excreting waste products. The observed range of 0.1 to 19.7 mg/dL is markedly elevated compared to normal values (0.0–0.3 mg/dL in adults.

Total Protein (TP) is the combined measurement of albumin and globulin levels in the blood and serves as an indicator of nutritional status and liver health. The observed values ranged from 2.7 to 9.6 g/dL, compared to normal ranges of 6.0–8.3 g/dL in adults.

Albumin (ALB), a protein synthesized by the liver, is essential for maintaining osmotic pressure and transporting various substances in the blood. The observed albumin levels ranged from 0.9 to 5.5 g/dL, whereas normal levels are 3.5–5.0 g/dL in adults.

The **Albumin/Globulin (A/G)** Ratio provides additional insight into liver and immune system health. In the dataset, the ratio varied between 0.3 and 2.8 while the normal range is 1.1–2.5 in adults.

Alkaline Phosphatase (ALP) is an enzyme associated with bile ducts and bone metabolism. Elevated levels often indicate liver disease or bone disorders. The observed range of 63 to 2110 U/L is significantly higher than the normal values of 44–147 U/L in adults.

Serum Glutamate Pyruvate Transaminase (SGPT/ALT) is a liver-specific enzyme that is highly sensitive to hepatocellular injury. The observed values ranged from 10 to 2000 U/L compared to normal levels of 7–56 U/L in adults. High value of SGPT levels are commonly associated with conditions such as hepatitis, fatty liver disease, and cirrhosis.

Serum Glutamate Oxaloacetate Transaminase (SGOT/AST) is another important enzyme used to assess liver function and detect tissue damage. The observed range of 10 to 4929 U/L far exceeds the normal limits of less than 40–45 U/L in adults , High value indicates severe liver injury, chronic disease, or possible drug-induced toxicity.

4. Methodologies:

This study employs a comparable machine learning approach to predict liver disease based on patients' clinical and biochemical attributes. Our methodology involves analysing and contrasting the efficacy of various supervised learning algorithms, demonstrating the superior predictive capability of ensemble learning via the use of a Voting Classifier model.

The technique encompasses data preparation, then AI Model building, Model assessment, and performance Evaluation across essential metrics, including Accuracy, Area Under the ROC Curve (AUC), and Precision

These traits are often associated with hepatic function and are widely recognized as critical indications of liver diseases.

The following fundamental processes constituted our data preparation:

a) Imputation Technique for Replacement of Missing Values: Absent data were supplemented using the mean.

b) Standardization for Qualitative Features: Z-score normalization was used to normalize continuous variables.

c) Encoding Categorical Variables: One-hot encoding transformed the categorical attribute from a text representation to a numerical format.

d) Data Splitting: We used stratified sampling to maintain the class distribution throughout the division of the dataset into training (80%) and testing (20%) subsets.

5. Ensemble ML Algorithms

The Ensemble Method in machine learning is a predictive approach that amalgamates numerous independent models called base learners to get a singular yet precise and resilient Algorithm.

Instead of depending on a single algorithm, ensemble approaches amalgamate the advantages of several models to diminish variance, bias and overfitting and hence enhance overall generalization performance.

Common ensemble methods include Bagging, such as Random Forest which builds independent models at the same time to reduce variance. Boosting like Gradient Boosting creates models in sequence to correct errors and Voting or Stacking combines predictions from different algorithms.

6. Measurement Matrix and Outcomes:

It includes a description of the metrics to be used to evaluate the performance of the ML classifiers that will be put into practice. The commonly used metrics of are accuracy, F1-score, Positive Predictive Value, True Positive Rate, True Negative Rate, ROC-AUC (Receiver Operating Characteristic – Area Under Curve), Cross-Entropy Loss.

The representation below indicates that the sample is marginally skewed, including 416 records for patients with liver illness and 167 records for individuals without.



Figure 6.1: Distribution of Hospital Patients from Raw Data with Hetapo-Diseases.

The below table show the Descriptive Statistics from the Predictor list

	Age	Total_Bilirubin	Direct_Bilirubin	Alkaline_Phosphotase	Alamine_Aminotransferase	Aspartate_Aminotransferase	Total_Protiens	Albumin	Albumin_and_Globulin_Ratio	target
count	583	583	583	583	583	583	583	583	579	583
mean	44.74614	3.298799	1.486106	290.5763	80.71355	109.9108	6.48319	3.141852	0.947064	0.713551
std	16.18983	6.209522	2.808498	242.938	182.6204	288.9185	1.085451	0.795519	0.319592	0.45249
min	4	0.4	0.1	63	10	10	2.7	0.9	0.3	0
25%	33	0.8	0.2	175.5	23	25	5.8	2.6	0.7	0
50%	45	1	0.3	208	35	42	6.6	3.1	0.93	1
75%	58	2.6	1.3	298	60.5	87	7.2	3.8	1.1	1
max	90	75	19.7	2110	2000	4929	9.6	5.5	2.8	1

Figure 6.2 : Descriptive Statistics of the Patient dataset

The diagram above illustrates the Pearson Correlation Matrix of the Predictor List, indicating that predictors such as Direct Bilirubin, Alkaline Phosphatase, and Age exhibit significantly greater correlations with the target compared to others.

	Total_Bilirubin	Direct_Bilirubin	Alkaline_Phosphotase	Alamine_Aminotransferase	Aspartate_Aminotransferase	Total_Protiens	Albumin	Albumin_and_Globulin_Ratio	target
Total_Bilirubin	1								
Direct_Bilirubin	0.874618	1							
Alkaline_Phosphotase	0.206669	0.234939	1						
Alamine_Aminotransferase	0.214065	0.233894	0.12568	1					
Aspartate_Aminotransferase	0.237831	0.257544	0.167196	0.791966	1				
Total_Protiens	-0.0081	-0.00014	-0.02851	-0.04252	-0.02565	1			
Albumin	-0.22225	-0.22853	-0.16545	-0.02974	-0.08529	0.784053	1		
Albumin_and_Globulin_Ratio	-0.20627	-0.20012	-0.23417	-0.00237	-0.07004	0.234887	0.689632	1	
target	0.220208	0.246046	0.184866	0.163416	0.151934	-0.03501	-0.16139	-0.16313	1

Figure 6.3: Pearson Correlation Matrix of the Predictor List

Table 6.1: Comparison of Multiple Algorithms and Proposed Strategy

Sl no	Algorithm	Accuracy	AUC Value of ROC Curve	Precision Score	Recall Score	F1 Score	Sensitivity
1	Logistics Regression	73.97260274	0.785377358	0.753731343	0.952830189	0.841666667	0.952830189
2	Random Forest Classifier	76.71232877	0.751768868	0.821428571	0.867924528	0.844036697	0.867924528
3	Extra Gradient Boost	71.23287671	0.710613208	0.780701754	0.839622642	0.809090909	0.839622642
4	Ada Boost	73.97260274	0.764740566	0.761538462	0.933962264	0.838983051	0.933962264
5	Gradient Boosting	78.76712329	0.784080189	0.781954887	0.981132075	0.870292887	0.981132075
6	SVM	73.28767123	0.757075472	0.751879699	0.943396226	0.836820084	0.943396226
7	Artificial Neural Network	76.02739726	0.8125	0.825688073	0.849056604	0.837209302	0.849056604
8	Voting Ensemble	78.76712329	0.824528302	0.804878049	0.933962264	0.864628821	0.933962264

7. Analysis and Conclusion

Liver diseases result in two million fatalities annually and impact numerous individuals globally. This research started with data processing using exploratory data analysis (EDA) to assess and evaluate the quality of the chosen dataset. The dataset has minimal missing values allowing us to investigate imputation strategies that take into account the data's characteristics.

The motivation for focusing on liver disease in this research is not arbitrary, it is grounded in a convergence of epidemiological urgency, clinical complexity, economic significance, diagnostic challenge, and research gap that collectively make it one of the most important and analytically tractable domains for AI-driven healthcare management innovation.

The silent progression of liver disease its devastating consequences when detected late its enormous economic burden. Its disproportionate impact l converges to establish liver disease prediction as a research focus of profound practical and scholarly significance.

We have evaluated the efficacy of several learning approaches, including Boosting, Bagging, and Voting. The results demonstrate that an advanced ensemble learning strategy incorporates predictive skills from individual AI algorithms such as Gradient Boosting (GB), Random Forest Classifier (RF), and Artificial

Neural Network (ANN). It improves overall model efficiency in key performance indicators (KPIs) including Accuracy, AUC, Precision etc

The suggested study is a viable and significant initiative that judiciously use AI to address two distinct issues in healthcare and insurance. The establishment of a cohesive AI Ensemble enhances diagnostic precision and establishes a new benchmark for data-driven Patient Risk Evaluation. This guarantees that the technology functions as a beneficial instrument for both patients and healthcare systems.

References

[1] Malik, S., Das, R., Thongtan, T., Thompson, K., & Dbouk, N. (2024). AI in hepatology: revolutionizing the diagnosis and management of liver disease. Journal of Clinical Medicine, 13(24), 7833.,

[2] Soliman, O. S., & Elhamd, E. A. (2014). Classification of hepatitis C virus using modified particle swarm optimization and least squares support vector machine. International Journal of Scientific & Engineering Research, 5(3), 122.

[3] Chen, Z. L., Wang, C., & Wang, F. (2025). Revolutionizing gastroenterology and hepatology with artificial intelligence: From precision diagnosis to equitable healthcare through interdisciplinary practice. World Journal of Gastroenterology, 31(24), 108021.

[4] Dritsas, E., & Trigka, M. (2023). Supervised machine learning models for liver disease risk prediction. Computers, 12(1), 19.

[5] Rui, L. (2014). Energy metabolism in the liver. Comprehensive physiology, 4(1), 177-197.

[6] Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., ... & Beckerman, R. (2016). The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology, 64(5), 1577-1586.

[7] Himmelstein, D. U., Jun, M., Busse, R., Chevreul, K., Geissler, A., Jeurissen, P., ... & Woolhandler, S. (2014). A comparison of hospital administrative costs in eight nations: US costs exceed all others by far. Health Affairs, 33(9), 1586-1594.

[8] Nahar N, Ara F, Neloy MAI, Barua V, Hossain MS, Andersson K. A comparative analysis of the ensemble method for liver disease prediction. In: in 2nd International conference on innovation in engineering and technology (ICIET). Dhaka, Bangladesh; 2019.

[9] Ramana, B. & Venkateswarlu, N. (2022). ILPD (Indian Liver Patient Dataset) [Dataset]. UCI Machine Learning Repository. https://doi.org/10.24432/C5D02C.

[10] Gupta K, Jiwani N, Afreen N, Divyarani D. Liver disease prediction using machine learning classification techniques, in 11th international conference on communication systems and network technologies (CSNT). Indore, India; 2022

[11] Babu, M. P., Ramjee, M., & Katta, S. (2016, August). Implementation of partitional clustering on ILPD dataset to predict liver disorders. In 2016 7th IEEE International Conference on Software Engineering and Service Science (ICSESS) (pp. 1094-1097). IEEE.